Cell cycle regulation is orchestrated by a complex network of interactions between proteins,
enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation …

Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

Background Lenalidomide plus dexamethasone is a reference treatment for patients with
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …

Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …